Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurotech International ( (AU:NTI) ) just unveiled an update.
Neurotech International has disclosed a change in director Mark Davies’ indirect shareholding, lodged under ASX listing rule 3.19A.2. The change relates to securities held through director-related entity Seivad Investments Pty Ltd
Davies’ indirect holding increased by 7,142,858 fully paid ordinary shares, for consideration of $100,000.01, raising his total interest from 11,793,017 to 18,935,875 shares. The new shares were issued pursuant to a shareholder-approved resolution, and the company confirmed the transaction did not occur during a closed trading period requiring special clearance.
The most recent analyst rating on (AU:NTI) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.
More about Neurotech International
Neurotech International Limited is an Australian-listed company in the healthcare and technology sector. It operates as a neurotechnology developer, with its activities centered around medical or therapeutic applications, and its shares are traded on the ASX, giving it access to public equity markets for growth and operations.
Average Trading Volume: 1,298,330
Technical Sentiment Signal: Sell
Current Market Cap: A$16.85M
See more insights into NTI stock on TipRanks’ Stock Analysis page.